The curious constraints on clofazimine Abstract. Clofazimine is a WHO-recommended therapy for multibacillary leprosy and an emerging option for drug-resistant tuberculosis and non-tuberculous my

Interesting piece on #clofazimine access in the USA and elsewhere from @akesselheim.bsky.social and colleagues.
"The curious constraints on clofazimine"
💊🌐
(as a bonus, nice to see someone out there actually reading some of my articles on access to old #EssentialMedicines in Canada😜)

Widespread genomic heterogeneity at the type II NAD(P)H dehydrogenase locus predisposes Cryptosporidium to clofazimine resistance The parasite Cryptosporidium is a leading cause of life-threatening diarrheal disease, and effective treatment is not available. The discovery of potent anti-Cryptosporidium activity of clofazimine, o...

Our latest story on Clofazimine resistance in Cryptosporidium! What started as a side project turned into one of the most interesting stories.

Genetics 101 😊

#Cryptosporidium #Apicomplexa #Clofazimine #AntimicrobialResistance #AMR #ParasiteResearch

www.biorxiv.org/content/10.1...

A loading dose of clofazimine to rapidly achieve steady-state-like concentrations in patients with nontuberculous mycobacterial disease AbstractObjectives. Clofazimine is a promising drug for the treatment of nontuberculous mycobacterial (NTM) diseases. Accumulation of clofazimine to reach

Interesting article in #JAC on loading dose of #clofazimine in nontuberculous mycobacterial disease. A 4-week loading dose of 300 mg daily resulted in faster time to steady-state-like concentrations (3.8 vs 5.3 months) and was deemed safe and well-tolerated.

doi.org/10.1093/jac/... #IDSky #NTM